BRPI0514447B8 - uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina - Google Patents

uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina

Info

Publication number
BRPI0514447B8
BRPI0514447B8 BRPI0514447A BRPI0514447A BRPI0514447B8 BR PI0514447 B8 BRPI0514447 B8 BR PI0514447B8 BR PI0514447 A BRPI0514447 A BR PI0514447A BR PI0514447 A BRPI0514447 A BR PI0514447A BR PI0514447 B8 BRPI0514447 B8 BR PI0514447B8
Authority
BR
Brazil
Prior art keywords
vaccine
human
preparation
immunodeficiency virus
accessory protein
Prior art date
Application number
BRPI0514447A
Other languages
English (en)
Inventor
Mangeney Marianne
Renard Martial
Heidmann Thierry
Original Assignee
Centre Nat Rech Scient
Roussy Inst Gustave
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Roussy Inst Gustave, Univ Paris Sud Xi filed Critical Centre Nat Rech Scient
Publication of BRPI0514447A publication Critical patent/BRPI0514447A/pt
Publication of BRPI0514447B1 publication Critical patent/BRPI0514447B1/pt
Publication of BRPI0514447B8 publication Critical patent/BRPI0514447B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

uso da função imunossupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina. trata-se do uso de uma mutação de pelo menos um aminoácido no domínio imunossupressor de uma proteína acessória de hiv ou de siv para a modulação da propriedade imunossupressora da proteína.
BRPI0514447A 2004-08-17 2005-08-17 uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina BRPI0514447B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292056 2004-08-17
EP04292056.1 2004-08-17
PCT/EP2005/008907 WO2006018289A1 (en) 2004-08-17 2005-08-17 Mutated hiv nef for modulating immunity

Publications (3)

Publication Number Publication Date
BRPI0514447A BRPI0514447A (pt) 2008-06-10
BRPI0514447B1 BRPI0514447B1 (pt) 2021-03-02
BRPI0514447B8 true BRPI0514447B8 (pt) 2021-05-25

Family

ID=34931346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514447A BRPI0514447B8 (pt) 2004-08-17 2005-08-17 uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina

Country Status (13)

Country Link
US (1) US8795685B2 (pt)
EP (2) EP2420248A1 (pt)
JP (1) JP4926060B2 (pt)
CN (1) CN101027084B (pt)
AU (1) AU2005274324B2 (pt)
BR (1) BRPI0514447B8 (pt)
CA (1) CA2577183C (pt)
DK (1) DK1778282T3 (pt)
ES (1) ES2572132T3 (pt)
IL (1) IL180921A (pt)
MX (1) MX2007001916A (pt)
WO (1) WO2006018289A1 (pt)
ZA (1) ZA200701180B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558126B (zh) * 2006-03-10 2020-02-14 派特塞尔有限公司 Hiv的调节或辅助蛋白的肽、组合物及它们的应用
US9682137B2 (en) 2011-12-07 2017-06-20 Viroxis Sas Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US9777042B2 (en) * 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
CN109836480B (zh) * 2017-11-29 2023-03-14 陈松明 一种重组免疫抑制蛋白
AU2019312411A1 (en) * 2018-07-26 2021-01-07 Legend Biotech Ireland Limited Nef-containing T cells and methods of producing thereof
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
JP2024502658A (ja) 2021-01-13 2024-01-22 ヴィロキシ 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079342A (en) * 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
AU608294B2 (en) * 1987-01-16 1991-03-28 Institut Pasteur Peptides having immunological properties 2-hiv-2
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
US5223423A (en) * 1989-03-31 1993-06-29 United States Of America Characterization of replication competent human immunodeficiency type 2 proviral clone hiv-2sbl/isy
CA2163212C (en) * 1993-05-18 2004-07-13 Ahmed Abdullah Azad Therapeutic compounds
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
FR2756843B1 (fr) * 1996-12-09 1999-01-22 Inst Nat Sante Rech Med Souches de vih-1 non-m non-o, fragments et applications
ATE306938T1 (de) 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
CA2439990A1 (en) 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US7312305B2 (en) * 2002-03-20 2007-12-25 Morehouse School Of Medicine Tumor cytotoxicity induced by modulators of the CXCR4 receptor

Also Published As

Publication number Publication date
CA2577183C (en) 2014-02-18
AU2005274324B2 (en) 2011-06-23
EP1778282B1 (en) 2016-03-30
JP2008509691A (ja) 2008-04-03
US8795685B2 (en) 2014-08-05
BRPI0514447A (pt) 2008-06-10
BRPI0514447B1 (pt) 2021-03-02
MX2007001916A (es) 2007-07-11
EP2420248A1 (en) 2012-02-22
CN101027084A (zh) 2007-08-29
CN101027084B (zh) 2012-02-22
WO2006018289A1 (en) 2006-02-23
IL180921A0 (en) 2007-07-04
CA2577183A1 (en) 2006-02-23
IL180921A (en) 2013-07-31
DK1778282T3 (en) 2016-06-06
EP1778282A1 (en) 2007-05-02
ES2572132T3 (es) 2016-05-30
JP4926060B2 (ja) 2012-05-09
US20080220008A1 (en) 2008-09-11
AU2005274324A1 (en) 2006-02-23
ZA200701180B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
BRPI0514447B8 (pt) uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
BRPI0511616A (pt) compostos
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ECSP088641A (es) Moduladores de indol sulfonamida de receptores de progesterona
BR112021019748A2 (pt) Degradadores de stat e usos dos mesmos
BRPI0516202A (pt) produto para alimentação de um animal, uso, kit e método de preparação deste produto
BRPI0411528A (pt) uso de isomalte como prebiótico
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ECSP088376A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
SE0301653D0 (sv) Novel compounds
BRPI0511079A (pt) usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
AR048534A1 (es) Formulaciones de acetato de bazedoxifeno
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
CY1110213T1 (el) Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων
BR112023005789A2 (pt) Composição farmacêutica compreendendo conjugado anticorpo-fármaco e uso de composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: INSTITUT GUSTAVE ROUSSY (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR)